期刊文献+

罗格列酮联合氯沙坦治疗糖尿病早期肾病疗效观察 被引量:3

下载PDF
导出
摘要 目的探讨罗格列酮联合氯沙坦治疗糖尿病早期肾病的疗效。方法将选择的38例病例随机分为2组,对照组给予口服西药降糖药或胰岛素,治疗组在对照组基础上加用罗格列酮和氯沙坦,观察期3个月,观察期间检测FBG,Cr,UAER,TG,CHOL和LDL-C的变化情况。结果治疗组在血糖控制上优于对照组(P<0.05);治疗组在降低UAER,Cr,CHOL和LDL-C方面优于对照组(P<0.05)。结论罗格列酮联合氯沙坦可有效控制糖尿病早期肾病患者的血糖,降低血脂,减少血肌酐和尿白蛋白排泄,防止肾小球硬化,保护肾功能。
出处 《西北药学杂志》 CAS 2009年第4期303-304,共2页 Northwest Pharmaceutical Journal
  • 相关文献

参考文献5

二级参考文献20

  • 1全国糖尿病研究协作组调查研究组.全国14省市30万人口中糖尿病调查报告[J].中华内科杂志,1981,20(11):678-678.
  • 2[3]UK Prospective Diabetes Study Group.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 38.Br Med J,1998,317:703-713.
  • 3[4]Parring HH.Initiation and progression of diabetic nephropathy.N Engl J Med,1996,335:1682-1683.
  • 4[5]Parring HH,Lehnert H,Broehner-Mortensen J,et al.Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group.The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.N Engl J Med,2001,345:870-878.
  • 5[6]Lewis EJ,Hunsicker LG,Clarke WR,et al.Renoprotective effect of the angiotensin-reeeptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.N Engl J Med,2001,345:851-860.
  • 6[8]Brenner BM,Cooper ME,De Zeeuw D,et al.RENAAL Study Investigators.Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.N Engl J Med,2001,345:861-869.
  • 7[9]The ONTARGET Investigators.Telmisartan,ramipril,or both in patients at high risk for vascular events.N EnglJ Med,2008,358:1547-1559.
  • 8Lister CA, Boam DS, Bretherton - Watt D, et al. Rosiglitazone increases pancreatic islet area, number and insulin content, but not insulin gene expression[ J]. Diabetologia , 1998,41 (Supplment 1) :A169 - 178
  • 9Finegood DT, McArthur MD, Kojwang D, et al. Beta - cell mass dynamics in Zueker diabetic fatty rats. Rosiglitazone prevents the Hse in net cell death[ J]. Diabetes,2001,50(5 ) : 1021 - 1029
  • 10Beales PE, Pozzilli P. Thiazolidinediones for the prevention of diabetes in the non - obses diabetic (NOD) mouse:implications for human type 1 diabetes[ J]. Diabetes Metab Bey,2002,51 (2) :114 - 117

共引文献10

同被引文献22

  • 1李斌.罗格列酮对糖尿病肾病患者CRP、IL-2、IL-6、TNF-α水平的影响[J].山东医药,2008,48(20):88-89. 被引量:11
  • 2张传洽.Jaffe速率法、电极法和酶法测定肌酐结果的比较[J].国际检验医学杂志,2006,27(3):283-284. 被引量:13
  • 3Brown JE, Onyango DJ, Ramanjaneya M, et al. Visfatinregulates insulin secretion, insulin receptor signalling and mRNA expression of diabetes-related genes in mouse pancreatic beta-cells [J]. J Mol Endocrinol,2010, 44(3) ..171-178.
  • 4Szamatowicz J, Kuz micki M, Telejko B, et al. Serum vis- latin concentration is elevated in pregnant women irre- spectively of the presence of gestational diabetes [J]. Ginekol Pol,2009,80(1) 114-18.
  • 5Haider DG,Schindler K, Mittermayer F, et al. Effect of rosiglitazone on visfatin and retinol-binding protein-4 plasma concentrations in HIV-positive patients [J]. Clin Pharmacol Ther, 2007,81 (4): 580-585.
  • 6Toruner F, Altinova AE, Bukan N, et al. Plasma visfatin concentrations in subjects with type 1 diabetes mellitus [J]. Horm Res, 2009,72 (1) : 33-37.
  • 7Adeghate E. Visfatin: structure,function and relation to diabetes mellitus and other dysfunctions [J]. Curr Med Chem,2008,15 (18) :1851-1862.
  • 8Sandeep S, Velmurugan K, Deepa R, et .al. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians[J]. Metabolism, 2007,56 (4): 565-570.
  • 9Beysen C, Murphy E J, Nagaraj a H, et al. A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes [J]. J Lipid Res, 2008,49 (12) : 2657-2663.
  • 10Rho YH, Chung CP, Solus JF, et aL Adipoeytokines, insulin resistance, and coronary atherosclerosis in rheumatoid ar- thritis [J]. Arthritis Rheum,2010,62(5) : 1259-1264.

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部